Additional trials of MDM2 antagonists in MF patients have led to reductions in spleen size, improvement of systemic symptoms, and reduction in the VAF of MPN driver mutations (NCT04097821, NCT04485260, NCT04640532). Here, MDM2 is linked to myeloproliferative neoplasm.